Eyetech reiterated by Merrill at neutral

Eyetech Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating following second-quarter results. Eyetech shares Friday declined $0.26, or 2.24%, to close at $11.37 on volume of 1,676,750 shares versus the three-month running average of 4,310,100 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.